公开(公告)号：EP1497438B1

公开(公告)日：2009-10-28

申请号：EP03753568.9

申请日：2003-04-24

申请人： Crucell Holland B.V.

发明人： VOGELS, Ronald ,  BOUT, Abraham

IPC分类号： C12N15/86

CPC分类号： C12N15/86 ,  A61K48/00 ,  A61K2039/525 ,  A61K2039/5256 ,  C12N2710/10343 ,  C12N2810/6018 ,  C12N2830/002

公开(公告)号：EP1196594A2

公开(公告)日：2002-04-17

申请号：EP00946537.8

申请日：2000-07-07

申请人： Crucell Holland B.V.

发明人： HAVENGA, Menzo ,  VOGELS, Ronald

IPC分类号： C12N15/34 ,  C12N15/86 ,  C12N15/10 ,  A61K48/00 ,  C07K14/705

CPC分类号： C12N15/86 ,  A61K48/00 ,  C07K14/005 ,  C07K14/705 ,  C12N7/00 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10344 ,  C12N2710/10345 ,  C12N2710/10352 ,  C12N2810/6018

摘要： The invention relates to the field of molecular genetics and medicine. The invention discloses a method for delivering a nucleic acid of interest to a host cell by means of a gene delivery vehicle based on adenoviral material, whereby said gene delivery vehicle delivers the nucleic acid to the host cell by associating with a binding site and/or a receptor present on CAR-negative cells, said binding site and/or receptor being a binding site and/or a receptor for adenovirus subgroups D and/or F.

公开(公告)号：EP2822968A1

公开(公告)日：2015-01-14

申请号：EP13708411.7

申请日：2013-03-07

申请人： Crucell Holland B.V.

发明人： KWAKS, Theodorus Hendrikus Jacobus ,  VOGELS, Ronald

IPC分类号： C07K16/10

CPC分类号： C07K16/1018 ,  A61K39/42 ,  A61K47/6841 ,  A61K2039/505 ,  C07K16/10 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/11

摘要： Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.

公开(公告)号：EP1497440B1

公开(公告)日：2008-08-20

申请号：EP03753569.7

申请日：2003-04-24

申请人： Crucell Holland B.V.

发明人： VOGELS, Ronald ,  HAVENGA, Menzo, Jans, Emco ,  ZUIJDGEEST, David, Adrianus, Theodorus

IPC分类号： C12N15/861

CPC分类号： C12N15/86 ,  A61K2039/5256 ,  C12N2710/10343 ,  C12N2840/20 ,  C12N2840/44

摘要： The present invention provides methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B 55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.

公开(公告)号：EP1159438B1

公开(公告)日：2008-07-30

申请号：EP00908116.7

申请日：2000-03-03

申请人： Crucell Holland B.V.

发明人： VOGELS, Ronald ,  SCHOUTEN, Govert, Johan ,  BOUT, Abraham

IPC分类号： C12N15/861 ,  C12N15/62 ,  C07K14/075 ,  A61K48/00

CPC分类号： C12N7/00 ,  C07K14/005 ,  C12N9/1211 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10352

摘要： The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably said virus capsid is an adenovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably joint related diseases.

公开(公告)号：EP1307573B1

公开(公告)日：2006-01-04

申请号：EP01974977.9

申请日：2001-08-09

申请人： Crucell Holland B.V.

发明人： HAVENGA, Menzo, Jans, Emco ,  VOGELS, Ronald ,  BOUT, Abraham

IPC分类号： C12N15/861 ,  A61K48/00 ,  C12N5/10 ,  A61P19/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/6018

摘要： The present invention relates to a gene delivery vehicle comprising a recombinant adenovirus having a tropism for a primary human chondrocyte. By efficiently transducing a nucleic acid of interest into a primary chondrocyte, said gene delivery vehicle is able to at least in part improve the counteraction of cartilage disease. In one embodiment said recombinant adenovirus comprises a deletion in the gene encoding for fiber protein, which is replaced by a nucleic acid sequence encoding at least part of a fiber protein of a B-type adenovirus.

公开(公告)号：EP1497438A1

公开(公告)日：2005-01-19

申请号：EP03753568.9

申请日：2003-04-24

申请人： Crucell Holland B.V.

发明人： VOGELS, Ronald ,  BOUT, Abraham

IPC分类号： C12N15/86

CPC分类号： C12N15/86 ,  A61K48/00 ,  A61K2039/525 ,  A61K2039/5256 ,  C12N2710/10343 ,  C12N2810/6018 ,  C12N2830/002

摘要： The invention relates to methods and means for the production of adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.

公开(公告)号：EP1322774A2

公开(公告)日：2003-07-02

申请号：EP01985258.1

申请日：2001-09-20

申请人： Crucell Holland B.V.

发明人： HAVENGA, Menzo ,  VOGELS, Ronald ,  BOUT, Abraham

IPC分类号： C12N15/861 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  A61K2039/5256 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/6018

摘要： Adenoviral vectors can be used in vaccines to cause antigen-presenting cells to display desired antigens. Disclosed is a vector and associated means and methods which transduce antigen-presenting cells better than currently available vectors, enabling the vector to be delivered in lower doses, and thus improving the efficiency of adenoviral vaccines technology.

公开(公告)号：EP1497440A2

公开(公告)日：2005-01-19

申请号：EP03753569.7

申请日：2003-04-24

申请人： Crucell Holland B.V.

发明人： VOGELS, Ronald ,  HAVENGA, Menzo, Jans, Emco ,  ZUIJDGEEST, David, Adrianus, Theodorus

IPC分类号： C12N15/861

CPC分类号： C12N15/86 ,  A61K2039/5256 ,  C12N2710/10343 ,  C12N2840/20 ,  C12N2840/44

摘要： The present invention provides methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B 55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.

公开(公告)号：EP1307573A2

公开(公告)日：2003-05-07

申请号：EP01974977.9

申请日：2001-08-09

申请人： Crucell Holland B.V.

发明人： HAVENGA, Menzo, Jans, Emco ,  VOGELS, Ronald ,  BOUT, Abraham

IPC分类号： C12N15/86 ,  A61K48/00 ,  C12N5/10 ,  A61P19/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/6018

摘要： The present invention relates to a gene delivery vehicle comprising a recombinant adenovirus having a tropism for a primary human chondrocyte. By efficiently transducing a nucleic acid of interest into a primary chondrocyte, said gene delivery vehicle is able to at least in part improve the counteraction of cartilage disease. In one embodiment said recombinant adenovirus comprises a deletion in the gene encoding for fiber protein, which is replaced by a nucleic acid sequence encoding at least part of a fiber protein of a B-type adenovirus.